Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 490

Compelling investment opportunities in healthcare

Identifying and investing in the next big long-term structural growth trend is one way for investors to differentiate themselves in a competitive market.

Doing this is an integral part of our investing process at Munro Partners and we call these major growth trends areas of interests. Innovative health is one of Munro’s key areas of interest and one that is developing and advancing rapidly.

Health offers fertile ground for innovation across areas like diagnostics and patient care, genetic sequencing, virtual reality, and surgical robots.

The COVID pandemic brought specific investment opportunities in vaccines and treatment, but innovative health has been on a structural growth trend for over a decade on the back of several key drivers.

The drivers of healthcare innovation

There is a lot going on in the global healthcare landscape and we believe the resulting investment opportunities from this structural change are shaped by the below three trends.

1. Demographic change

Demographic change is having a real impact on healthcare as populations age across the developed world. Life expectancy has improved dramatically over the past 30 years. A baby born in Australia in 2020 can now expect to live to 81.2 years for a boy and 85.3 years for a girl, whereas in 1990 the equivalent figures were 73.9 and 80.1 years respectively.

The Baby Boomers, with higher expectations around their standard of living, are now between 58 and 76 years old.

A consequence of living longer is that many people end up with chronic conditions that need to be managed. For example, 46% of Australians aged over 65 suffer from two or more chronic conditions, compared with just 11% of those aged 15-44. Nearly half of all Australians aged over 75 have arthritis, and one in five has osteoporosis.

Not only do we have more diseases or medical conditions, but we are also expecting better care when we have them and are often prepared to pay for this superior care.

These demographic changes mean that disease prevention, treatment, and lifestyle management for the older members of society is a massive and growing subsector of the healthcare industry.

2. New technologies

Technology is making headway in healthcare, and companies across the spectrum - from start-up biotech pioneers to global pharmaceutical giants - are inventing new products and processes to assist in diagnosing, treating or curing diseases. More efficient healthcare provision is also a focus.

Predictive analytics in the field of artificial intelligence is also helping hospitals to better manage patient volumes and staff-to-patient ratios. And in surgery, micro robotics are being used in surgical treatments previously considered dangerous and invasive.

Innovations in the fields of genomics and gene therapy techniques are also important. These advances could be the start of a new era of personalised medicine as opposed to old-style generic treatment plans for all patients with the same diagnosis.

All of these innovations are huge and not only do they help in improving the health of everyone on the planet, they also offer a range of potential opportunities for long-term growth investors.

3. The rising cost of healthcare

This brings us to cost. Early-stage innovation technology is rarely cheap, and global spending on health climbed to US$8.5 trillion in 2019, or 9.8% of global gross domestic product (GDP), according to the World Health Organisation.

Unsurprisingly, health spending per capita in high-income countries was more than four times higher than in low-income countries, with the US healthcare system alone accounting for 42% of total global health spending.

There are therefore investment opportunities available in products, processes and systems that can reduce the cost of healthcare.

Lessons from Covid

As the pandemic spread around the world, the race to develop a successful vaccine to inoculate as many as possible began. But rather than pick a winner, in terms of what companies might emerge with the winning vaccine formula, at Munro Partners we decided to focus on the supply chain. We researched a wealth of opportunities and ended up focussing on companies in the biologics ecosystem which were critical in the development of the next generation mRNA (messenger ribonucleic acid) vaccines.

Biologic drugs are unique in that they are developed from cell culture media or living organisms rather than via a chemical synthesising process. Because of this, biologic drugs can specifically target the disease they’re designed to attack. This means they usually have a much higher efficacy and fewer side effects.

We looked to the supply chain for biologic drug companies and found investment opportunities in the companies supplying the consumable equipment needed by the vaccine producers, a strategy we saw as akin to investing in the picks and shovels that enabled the gold rush.

A stock story: Danaher Corporation

One such company is Danaher Corporation in the US. This is currently Munro's biggest position in innovative health and a company we were investing in long before Covid.

Danaher is a specialist in life science products, which make up over 50% of group profits, and is a major provider of the consumable products on which biologic drug developers rely. These products include filtration equipment and cell culture products, which provide a very high recurring revenue stream for the company. Danaher was also quick to develop Covid tests when the pandemic hit.

As biologic drugs take further market share from synthetically produced drugs, Danaher is in a good position to benefit. It has also made a number of strategic acquisitions including GE's bio-pharma business GE Healthcare Life Sciences, which it acquired in 2020 and renamed Cytivia. It is now a standalone operating company within Danaher's life sciences division.

To the future

In terms of innovative health, the long-term outlook will increasingly be about advances in cell and gene therapies, and genomics. Companies that supply those developing the vaccines and other therapies, like Danaher, are uniquely placed to benefit and where we see some of the biggest investment opportunities.

 

Jeremy Gibson is a partner and portfolio manager at Munro Partners. Munro is a specialist investment manager partner of GSFM Funds Management, a sponsor of Firstlinks. The information included in this article is provided for informational purposes only. Munro Partners do not represent that this information is accurate and complete, and it should not be relied upon as such. Any opinions expressed in this material reflect our judgment at this date, are subject to change and should not be relied upon as the basis of your investment decisions.

For more articles and papers from GSFM and partners, click here.

 

RELATED ARTICLES

The health care breakthrough that’s not an obesity drug

Investing in biotech and pharma

5 key investment themes for the next decade

banner

Most viewed in recent weeks

16 ASX stocks to buy and hold forever, updated

This time last year, I highlighted 16 ASX stocks that investors could own indefinitely. One year on, I look at whether there should be any changes to the list of stocks as well as which companies are worth buying now. 

UniSuper’s boss flags a potential correction ahead

The CIO of Australia’s fourth largest super fund by assets, John Pearce, suggests the odds favour a flat year for markets, with the possibility of a correction of 10% or more. However, he’ll use any dip as a buying opportunity.

2025-26 super thresholds – key changes and implications

The ABS recently released figures which are used to determine key superannuation rates and thresholds that will apply from 1 July 2025. This outlines the rates and thresholds that are changing and those that aren’t.  

Is Gen X ready for retirement?

With the arrival of the new year, the first members of ‘Generation X’ turned 60, marking the start of the MTV generation’s collective journey towards retirement. Are Gen Xers and our retirement system ready for the transition?

Why the $5.4 trillion wealth transfer is a generational tragedy

The intergenerational wealth transfer, largely driven by a housing boom, exacerbates economic inequality, stifles productivity, and impedes social mobility. Solutions lie in addressing the housing problem, not taxing wealth.

What Warren Buffett isn’t saying speaks volumes

Warren Buffett's annual shareholder letter has been fixture for avid investors for decades. In his latest letter, Buffett is reticent on many key topics, but his actions rather than words are sending clear signals to investors.

Latest Updates

Investing

Designing a life, with money to spare

Are you living your life by default or by design? It strikes me that many people are doing the former and living according to others’ expectations of them, leading to poor choices including with their finances.

Investment strategies

A closer look at defensive assets for turbulent times

After the recent market slump, it's a good time to brush up on the defensive asset classes – what they are, why hold them, and how they can both deliver on your goals and increase the reliability of your desired outcomes.

Financial planning

Are lifetime income streams the answer or just the easy way out?

Lately, there's been a push by Government for lifetime income streams as a solution to retirement income challenges. We run the numbers on these products to see whether they deliver on what they promise.

Shares

Is it time to buy the Big Four banks?

The stellar run of the major ASX banks last year left many investors scratching their heads. After a recent share price pullback, has value emerged in these banks, or is it best to steer clear of them?

Investment strategies

The useful role that subordinated debt can play in your portfolio

If you’re struggling to replace the hybrid exposure in your portfolio, you’re not alone. Subordinated debt is an option, and here is a guide on what it is and how it can fit into your investment mix.

Shares

Europe is back and small caps there offer significant opportunities

Trump’s moves on tariffs, defence, and Ukraine, have awoken European Governments after a decade of lethargy. European small cap manager, Alantra Asset Management, says it could herald a new era for the continent.

Shares

Lessons from the rise and fall of founder-led companies

Founder-led companies often attract investors due to leaders' personal stakes and long-term vision. But founder presence alone does not guarantee success, and the challenge is to identify which ones will succeed in the long term.

Sponsors

Alliances

© 2025 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. To the extent any content is general advice, it has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.